Put companies on watchlist
Merck & Co.
ISIN: US58933Y1055
WKN: A0YD8Q
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Merck & Co. · ISIN: US58933Y1055 · PR Newswire (ID: 20250407NY58127)
07 April 2025 11:45AM

Shareholders that lost money on Merck & Co., Inc.(MRK) should contact The Gross Law Firm about pending Class Action - MRK


NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).

Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=140971&from=4

CLASS PERIOD: February 3, 2022 to February 3, 2025

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' statements included, among other things, confidence in Merck's purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil's growth in China.  The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China "through at least midyear" to facilitate a "rapid reduction of inventory." Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had "not recovered to the level we had expected."  Following this news, Merck's common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck's stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day.

DEADLINE: April 14, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=140971&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MRK during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 14, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm

15 West 38th Street, 12th floor

New York, NY, 10018

Email: dg@securitiesclasslaw.com

Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-merck--co-incmrk-should-contact-the-gross-law-firm-about-pending-class-action---mrk-302421215.html

SOURCE The Gross Law Firm

Visual performance / price development - Merck & Co.
Smart analysis and research tools can be found here.
MIC: XNYS
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Contact:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942